AlloVir Approves Executive Bonuses for Potential 2024 Buyout
Company Announcements

AlloVir Approves Executive Bonuses for Potential 2024 Buyout

AlloVir (ALVR) has issued an update.

AlloVir, Inc.’s board, guided by its compensation committee, has sanctioned a potential $100,000 cash bonus for three top executives, contingent on sealing a change of control deal within the 2024 fiscal year. The bonuses hinge on both the successful negotiation of this strategic transaction and the executives remaining with the company until its completion. Notably, the CEO and CFO did not participate in the vote concerning their own bonuses.

See more data about ALVR stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAlloVir and Kalaris Merge to Advance Retinal Therapies
TheFlyAlloVir to combine with Kalaris Therapeutics in all-stock transaction
TipRanks Auto-Generated NewsdeskAlloVir Finalizes $7 Million Lease Termination Deal
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App